Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of bi-daily weekly ModraDoc006 + ritonavir maintenance therapy in non-small cell lung cancer
NL-OMON42448Phase 1Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 and ritonavir in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Dose-limiting toxicity and MTD/RP2D. Planned start Jun 2015; status: withdrawn.
02
Drugs
ModraDoc006ritonavir
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON42448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42448.